0001209191-19-026038.txt : 20190425
0001209191-19-026038.hdr.sgml : 20190425
20190425185621
ACCESSION NUMBER: 0001209191-19-026038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190423
FILED AS OF DATE: 20190425
DATE AS OF CHANGE: 20190425
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azelby Robert
CENTRAL INDEX KEY: 0001656998
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36431
FILM NUMBER: 19768814
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALDER BIOPHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001423824
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11804 NORTH CREEK PARKWAY SOUTH
CITY: BOTHELL
STATE: WA
ZIP: 98011
BUSINESS PHONE: 425-205-2900
MAIL ADDRESS:
STREET 1: 11804 NORTH CREEK PARKWAY SOUTH
CITY: BOTHELL
STATE: WA
ZIP: 98011
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-23
0
0001423824
ALDER BIOPHARMACEUTICALS INC
ALDR
0001656998
Azelby Robert
11804 NORTH CREEK PARKWAY SOUTH
BOTHELL
WA
98011
1
1
0
0
President and CEO
Stock Option (Right to Buy)
16.20
2019-04-23
4
A
0
150000
0.00
A
2019-04-23
2028-06-12
Common Stock
150000
150000
D
On June 13, 2018, the Reporting Person was granted an option to purchase 150,000 shares of Issuer's Common Stock (the "Option"). The Option vests upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone"). On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 150,000 shares subject to the Option.
/s/ Alan Hambelton, Attorney-in-Fact
2019-04-25